



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 3, 2019: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)
- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**
- **Medical Director Update** **6:40 - 6:45**
- **Follow-up Items from Previous Meetings** **6:45 - 6:50**
 - Analgesics: Topical Lidocaine Patch
- **RetroDUR/ProDUR** **6:50- 7:15**
 - Introduce: Long Term Antibiotic Use
 - Data Presentation: Appropriate Use of Asthma Controller Medications
- **Clinical Update: Drug Reviews** **7:15-7:45**
(Public comment prior to Board action)

Biosimilar Drug Reviews

- None at this time

Full New Drug Reviews

(Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)

- Beser lotion® (fluticasone propionate)
 - Diacomit® (stiripentol)
 - Duobrii® (halobetasol propionate and tazarotene)
 - Evenity® (romosozumab)
 - Jornay PM® (methylphenidate)
 - Mavenclad® (cladribine)
 - Mayzent® (siponimod)
 - Oxervate® (cenegermin-bkbj)
 - Qmiiz ODT® (meloxicam)
 - Rocklatan® (netarsudil and latanoprost)
 - Ruzurgi® (amifampridine)
 - Skyrizi® (risankizumab)
- **New Managed Therapeutic Drug Classes** **7:45 -7:45**

(Public comment prior to Board action)

- None at this time

▪ **Therapeutic Drug Classes – Periodic Review**

7:45 - 8:25

(Public comment prior to Board action)

- Anticoagulants
- Antidepressants, Other
- Antidepressants, SSRIs
- Antiparkinson's Agents
- Gastrointestinal Ulcer Therapies
- H. Pylori Combination Treatments
- Hyperuricemia and Gout
- Platelet Aggregation Inhibitors and Intermittent Claudication

▪ **Review of Newly-Developed/Revised Criteria**

8:25 - 8:25

(Public comment prior to Board action)

- None at this time

▪ **General Announcements**

8:25 – 8:30

Selected FDA Safety Alerts

Sanofi Provides Update on Precautionary Voluntary Recall of Zantac OTC in U.S.

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us?utm_campaign=FDA%20MedWatch%20-%20Zantac%20150%2C%20Zantac%20150%20Cool%20Mint%2C%20Zantac%2075%20%28OTC%20Products%29%20by%20Sanofi&utm_medium=email&utm_source=Eloqua#recall-announcement

▪ **Adjourn**

8:30